PitchSend

Investor Presentaiton

20 Published VGX-3100 Phase 2b Study Achieves All Primary and Secondary Endpoints Phase 2b Endpoints (n=167) Primary: Secondary: VGX-3100 Specific T Cells¹ 800 600 400 200 Regression to CIN1 or Normal 49.5% P=0.017 Regression of CIN3 & HPV to normal Regression to Normal AND Virological Clearance 40.2% P=0.003 T Cell Responses Measured in Blood * * * * Pre VGX-3100 Placebo 5 10 15 20 25 30 35 40 Study Week Treatment at wks 0, 4, & 12 *Statistically significant; bars are 95% CI Trimble et al. Lancet 2015 Post Week 36 Week 0 Increased and persistent presence of CD8+ cells (24 weeks post-last dose) IHC Staining: HPV IHC Staining: CD8 + CD8+ T Cell Infiltration INOVIO POWERING DNA MEDICINES

View entire presentation